1 Lozano, R. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England) 380, 2095–2128 (2012).

2 Top 10 causes of death. WHOhttp://www.who.int/mediacentre/factsheets/fs310/en (2017).

3 Plotkin, S. A. Vaccines: past, present and future. Nat. Med. 11, S5–S11 (2005).

4 De Clercq, E. & Li, G. Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695–747 (2016).

5 De Clercq, E. Strategies in the design of antiviral drugs. Nat. Rev. Drug Discov. 1, 13–25 (2002).

6 Fridland, A., Connelly, M. C. & Robbins, B. L. Cellular factors for resistance against antiretroviral agents. Antivir. Ther. 5, 181–185 (2000).

7 Spillmann, D. Heparan sulfate: anchor for viral intruders? Biochimie 83, 811–817 (2001).

8 Cagno, V. et al. Highly sulfated K5 Escherichia coli polysaccharide derivatives inhibit respiratory syncytial virus infectivity in cell lines and human tracheal-bronchial histocultures. Antimicrob. Agents Chemother. 58, 4782–4794 (2014).

9 Lembo, D. et al. Auto-associative heparin nanoassemblies: a biomimetic platform against the heparan sulfate-dependent viruses HSV-1, HSV-2, HPV-16 and RSV. Eur. J. Pharmaceutics Biopharmaceutics: Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik e.V 88, 275–282 (2014).

10 Rusnati, M. et al. Sulfated K5 Escherichia coli polysaccharide derivatives: a novel class of candidate antiviral microbicides. Pharmacol. Ther. 123, 310–322 (2009).

11 Klimyte, E. M., Smith, S. E., Oreste, P., Lembo, D. & Dutch, R. E. Inhibition of human metapneumovirus binding to heparan sulfate blocks infection in human lung cells and airway tissues. J. Virol. 90, 9237–9250 (2016).

12 Riblett, A. M. et al. A haploid genetic screen identifies heparan sulfate proteoglycans supporting Rift Valley fever virus infection. J. Virol. 90, 1414–1423 (2015).

13 Donalisio, M. et al. The AGMA1 poly(amidoamine) inhibits the infectivity of herpes simplex virus in cell lines, in human cervicovaginal histocultures, and in vaginally infected mice. Biomaterials 85, 40–53 (2016).

14 Cagno, V. et al. The agmatine-containing poly(amidoamine) polymer AGMA1 binds cell surface heparan sulfates and prevents attachment of mucosal human papillomaviruses. Antimicrob. Agents Chemother. 59, 5250–5259 (2015).

15 Baram-Pinto, D., Shukla, S., Gedanken, A. & Sarid, R. Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles. Small 6, 1044–1050 (2010).

16 Bergstrom, D. E. et al. Polysulfonates derived from metal thiolate complexes as inhibitors of HIV-1 and various other enveloped viruses in vitro. Antivir. Chem. Chemother. 13, 185–195 (2002).

17 Bowman, M.-C. et al. Inhibition of HIV fusion with multivalent gold nanoparticles. J. Am. Chem. Soc. 130, 6896–6897 (2008).

18 Scordi-Bello, I. A. et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob. Agents Chemother. 49, 3607–3615 (2005).

19 McCormack, S. et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet 376, 1329–1337 (2010).

20 Pirrone, V., Wigdahl, B. & Krebs, F. C. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antivir. Res. 90, 168–182 (2011).

21 Van Damme, L. et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. New Engl. J. Med. 359, 463–472 (2008).

22 Shogan, B., Kruse, L., Mulamba, G. B., Hu, A. & Coen, D. M. Virucidal activity of a GT-rich oligonucleotide against herpes simplex virus mediated by glycoprotein B. J. Virol. 80, 4740–4747 (2006).

23 Bastian, A. R. et al. Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120. ChemMedChem 6, 1335–1339 (2011).

24 de Souza e Silva, J. M. et al. Viral inhibition mechanism mediated by surface-modified silica nanoparticles. ACS Appl. Mater. Interfaces 8, 16564–16572 (2016).

25 Bromberg, L. et al. Antiviral properties of polymeric aziridine- and biguanide-modified core-shell magnetic nanoparticles. Langmuir 28, 4548–4558 (2012).

26 Broglie, J. J. et al. Antiviral activity of gold/copper sulfide core/shell nanoparticles against human norovirus virus-like particles. PLoS ONE 10, e0141050 (2015).

27 Lara, H. H., Garza-Trevino, E. N., Ixtepan-Turrent, L. & Singh, D. K. Silver nanoparticles are broad-spectrum bactericidal and virucidal compounds. J. Nanobiotechnology 9, 30 (2011).

28 Chen, N. N., Zheng, Y., Yin, J. J., Li, X. J. & Zheng, C. L. Inhibitory effects of silver nanoparticles against adenovirus type 3 in vitro. J. Virol. Methods 193, 470–477 (2013).

29 Abe, M. et al. Effects of several virucidal agents on inactivation of influenza, Newcastle disease, and avian infectious bronchitis viruses in the allantoic fluid of chicken eggs. Jpn. J. Infect. Dis. 60, 342–346 (2007).

30 Chaudhuri, A., Battaglia, G. & Golestanian, R. The effect of interactions on the cellular uptake of nanoparticles. Phys. Biol. 8, 046002 (2011).

31 Lipowsky, R. & Dobereiner, H. G. Vesicles in contact with nanoparticles and colloids. Europhys. Lett. 43, 219–225 (1998).

32 Sabella, S. et al. A general mechanism for intracellular toxicity of metal-containing nanoparticles. Nanoscale 6, 7052–7061 (2014).

33 Huang, R. X., Carney, R. P., Stellacci, F. & Lau, B. L. T. Colloidal stability of self-assembled mono layer-coated gold nanoparticles: the effects of surface compositional and structural heterogeneity. Langmuir 29, 11560–11566 (2013).

34 Huang, R. X., Carney, R. P., Stellacci, F. & Lau, B. L. T. Protein-nanoparticle interactions: the effects of surface compositional and structural heterogeneity are scale dependent. Nanoscale 5, 6928–6935 (2013).

35 Huang, R. X., Carney, R. R., Ikuma, K., Stellacci, F. & Lau, B. L. T. Effects of surface compositional and structural heterogeneity on nanoparticle-protein interactions: different protein configurations. ACS Nano 8, 5402–5412 (2014).

36 Bathia, S., Cuellar Camacho, L. & Haag, R. Pathogen inhibition by multivalent ligand architectures. J. Am. Chem. Soc. 138, 8654–8666 (2016).

37 Dasgupta, J. et al. Structural basis of oligosaccharide receptor recognition by human papillomavirus. J. Biol. Chem. 286, 2617–2624 (2011).

38 Knappe, M. et al. Surface-exposed amino acid residues of HPV16 l1 protein mediating interaction with cell surface heparan sulfate. J. Biol. Chem. 282, 27913–27922 (2007).

39 Qian, E. Q. et al. Atomically precise organomimetic cluster nanomolecules assembled via Perfluoroaryl-Thiol SNAr Chemistry. Nat. Chem. 9, 333–340 (2016).

40 Matulis, D. & Lovrien, R. 1-Anilino-8-naphthalene sulfonate anion-protein binding depends primarily on ion pair formation. Biophys. J. 74, 422–429 (1998).

41 Melcrova, A. et al. The complex nature of calcium cation interactions with phospholipid bilayers. Sci. Rep. 6, 38035 (2016).

42 Verma, A. et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7, 588–595 (2008).